Drug Information

Drug General Information
Drug ID
D00GNK
Former ID
DCL000156
Drug Name
LY293111
Drug Type
Small molecular drug
Indication Pancreatic cancer [ICD9: 140-199, 140-229, 157, 210-229; ICD10:C25] Discontinued in Phase 2 [539959], [545441]
Therapeutic Class
Anticancer Agents
Company
Sawyer & Brooks
Structure
Download
2D MOL

3D MOL
Formula
C33H33FO6
InChI
InChI=1S/C33H33FO6/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37)
InChIKey
YFIZRWPXUYFCSN-UHFFFAOYSA-N
CAS Number
CAS 161172-51-6
PubChem Compound ID
177941
PubChem Substance ID
11548587, 14812486, 33501282, 47206030, 47510093, 47880127, 50941392, 57395580, 85210083, 103297519, 103938520, 104426797, 125333748, 129787932, 134338835, 134339331, 135203117, 137140708, 143268590, 163122508, 178100247, 198959012, 204369926, 224993996, 227838792, 252215379, 252467565
Target and Pathway
Target(s) Leukotriene B4 receptor 1 Target Info Antagonist [536139], [536318], [537053]
KEGG Pathway Neuroactive ligand-receptor interaction
NetPath Pathway IL4 Signaling Pathway
Reactome Leukotriene receptors
G alpha (q) signalling events
WikiPathways Nucleotide GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Spinal Cord Injury
GPCR ligand binding
GPCR downstream signaling
References
Ref 539959(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2948).
Ref 545441Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003262)
Ref 536139Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia. 2005 Nov;19(11):1977-84.
Ref 536318A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Invest New Drugs. 2007 Jun;25(3):217-25. Epub 2006 Dec 5.
Ref 537053The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer. PPAR Res. 2008;2008:827096. Epub 2009 Jan 27.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.